RSV Prevention Strategies for Infants: Latest Updates

Okay, here’s a breakdown of the references provided, formatted for clarity:

1. FDA Label for Beyfortus⁣ (Nirsevimab)

* Source: ‍ U.S. Food⁤ and Drug Management (FDA)
* Link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103770s5185lbl.pdf

* ‍ Date accessed: Not explicitly stated, but the label is from 2014.

2.Centers ‍for Disease Control and Prevention (CDC) – RSV Immunization Guidance

* Source: Centers for Disease Control and Prevention⁤ (CDC)
* Link: https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html

* ⁣ Date Accessed: August 28, 2025
* Date Updated: August 2025

3. Hammitt⁣ et al. – Nirsevimab Efficacy Study (NEJM)

* ‍ Authors: Hammitt LL, ‍Dagan R, Yuan Y, et al.
*⁢ Title: Nirsevimab for prevention of RSV in healthy late-preterm and term infants.
* Journal: New england ⁤Journal of Medicine (N engl j with)
* ⁣ Year: 2022
* Volume/Issue/Pages: 386(9):837-846
* ⁤ DOI: 10.1056/NEJMoa2110275

4. Griffin et al. – Nirsevimab Safety & Efficacy in High-risk Infants (NEJM)

* Authors: Griffin ⁢MP, Yuan Y, Takas T, et al.
* Title: ⁤Safety and efficacy of nirsevimab for ⁢RSV in infants with heart or lung disease or prematurity.
* ‍⁣ Journal: New England Journal of Medicine (N engl j ⁣with)
* Year: 2022
* Volume/Issue/Pages: 386(9):892-894
* DOI: 10.1056/Nejmc2112186

5. Griffin MP, Kargiannak

* This reference is incomplete. It appears⁤ to be the start of another citation,but it’s cut off.

Key Observations:

* The references primarily focus on Nirsevimab (Beyfortus), a monoclonal antibody used for RSV prevention.
* There’s ⁢a mix of primary research articles (published in the New England Journal‍ of Medicine) and guidance documents from regulatory/public ⁣health agencies (FDA and CDC).
* The dates of the references⁣ indicate the ⁢facts is relatively current (2022-2025).
* The formatting is a bit messy due to the source code included, but I’ve cleaned it up for readability.